CEO
Systemic Bio, a 3D Systems company
Systemic Bio develops vascularized organ models using hydrogels and human cells, enabling more accurate preclinical drug testing. Their proprietary 3D Systems technology offers significantly larger build volumes and higher resolution than existing methods, facilitating the creation of customizable organ-on-chip systems for drug discovery.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$15MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current preclinical drug testing methods often lack human relevance, leading to inaccurate predictions of drug efficacy and toxicity in humans. Existing organ-on-a-chip systems have limited build volumes and resolution, hindering the creation of complex, realistic organ models.
Solution
Systemic Bio develops human vascularized integrated organ systems (h-VIOS™) using hydrogels and human cells to create more accurate preclinical drug testing models. Their proprietary 3D printing platform offers significantly larger build volumes and higher resolution compared to existing technologies, enabling the creation of customizable organ models with dynamic perfusion. These models can be seeded with various cell types, including primary cells, cell lines, and stem cells, allowing for the study of drug effects in a human-relevant microenvironment. The platform supports up to 32 vascularized hydrogels in one plate, providing a scalable solution for drug discovery and development.
Target Audience
The primary customers are pharmaceutical companies and research institutions involved in preclinical drug discovery and development.
Features
- Proprietary 3D printing technology with 10x greater build volume and 10x higher resolution than commercially available technologies
- Customizable vascular architectures within hydrogel scaffolds
- Dynamic perfusion system for nutrient and waste exchange
- Compatibility with primary cells, cell lines, and stem cells
- Scalable platform supporting up to 32 vascularized hydrogels in one plate